UPS pours $48 million into cold chain facilities as the biologics boom reshapes logistics

TL;DR

UPS is investing $48 million in 27 temperature-controlled freight facilities across three continents as demand for biologics and GLP-1 drugs reshapes pharmaceutical logistics. The company is targeting $20 billion in healthcare revenue by end of 2026.

UPS has announced a $48 million investment in 27 temperature-controlled freight cross-dock facilities spanning the Americas, Europe, and Asia. The facilities are designed for short-term storage between air and ground movements while maintaining specific temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius, and frozen, according to the company.

The investment is the latest chapter in a broader strategic pivot for UPS, which is building a real-time digital twin of its entire logistics network and has spent billions on acquisitions to become what it calls the world’s leading provider of complex healthcare logistics. The company is targeting $20 billion in healthcare revenue by the end of 2026, a figure that would represent roughly 18 per cent of its total sales.

Why cold chain matters now

The pharmaceutical industry is shifting toward medicines that spoil. Roughly one in three newly approved drugs is now a biologic, and more than 85 per cent of those require temperature-controlled handling, according to PharmaSource.

The 💜 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!

The market for temperature-sensitive biologics is projected to expand at an 8.3 per cent compound annual growth rate through 2033, reaching an estimated $39.1 billion, according to Growth Market Reports. Much of that growth is being driven by GLP-1 injectables such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, cell and gene therapies, and mRNA platforms.

The cost of getting it wrong

Cold chain failures are not a hypothetical risk. Industry estimates put the global cost of temperature excursions at up to $35 billion annually, and the World Health Organisation has estimated that improper temperature management contributes to up to 50 per cent of global vaccine waste.

“We have aligned our investments with our healthcare customers’ specialised needs,” said Kate Gutmann, executive vice president and president of international, healthcare, and supply chain solutions at UPS. “We are helping patients access the medications and treatments they need.”

Acquisitions built the network

The cross-dock expansion builds on a series of acquisitions that have transformed UPS Healthcare from a side business into a core growth engine. The company paid $1.6 billion for Canada’s Andlauer Healthcare Group in 2025, adding specialised cold chain transportation across North America.

Earlier deals brought in Italy’s Bomi Group, which added temperature-controlled facilities in 14 countries and more than 350 refrigerated vehicles, along with European cold chain operators Frigo Trans and BPL. UPS also expanded its Incheon air hub in South Korea, a market that imported nearly $9.7 billion in pharmaceutical products in 2025.

A $20 billion target

UPS Healthcare now operates 19.2 million square feet of cGMP and GDP-compliant distribution space globally. The unit posted its first $3 billion revenue quarter in the first three months of 2026, putting it on track to hit the $20 billion annual target chief executive Carol Tomé set when she made healthcare the company’s top strategic priority.

The pharmaceutical industry’s pipeline suggests the demand will only intensify. As AI-designed therapies and digitised patient pathways push more temperature-sensitive treatments toward market, the parcel companies that can keep a vial at 4 degrees Celsius from a factory in Basel to a clinic in Seoul will have a logistics moat that is difficult to replicate.